T1	PROC 46 118	Estudio multicéntrico aleatorizado, doble ciego y controlado con placebo
T2	PROC 124 152	tratamiento de mantenimiento
#1	AnnotatorNotes T2	C0677908; Maintenance therapy; Therapeutic or Preventive Procedure
T3	PROC 201 235	evaluar la eficacia y la seguridad
#2	AnnotatorNotes T3	C0511730; Identify product efficacy and safety issues; Health Care Activity
T4	DISO 267 286	enfermedad de Crohn
#3	AnnotatorNotes T4	C0010346; Crohn Disease; Disease or Syndrome
T5	PROC 304 328	tratamiento de inducción
#4	AnnotatorNotes T5	C0857127; Induction procedure; Therapeutic or Preventive Procedure
T6	PROC 385 457	Estudio multicentrico aleatorizado, doble ciego y controlado con placebo
T7	PROC 463 491	tratamiento de mantenimiento
#5	AnnotatorNotes T7	C0677908; Maintenance therapy; Therapeutic or Preventive Procedure
T8	PROC 540 574	evaluar la eficacia y la seguridad
#6	AnnotatorNotes T8	C0511730; Identify product efficacy and safety issues; Health Care Activity
T9	DISO 606 625	enfermedad de Crohn
#7	AnnotatorNotes T9	C0010346; Crohn Disease; Disease or Syndrome
T10	PROC 643 667	tratamiento de inducción
#8	AnnotatorNotes T10	C0857127; Induction procedure; Therapeutic or Preventive Procedure
T11	DISO 766 785	Enfermedad de Crohn
#9	AnnotatorNotes T11	C0010346; Crohn Disease; Disease or Syndrome
T12	DISO 811 830	Enfermedad de Crohn
#10	AnnotatorNotes T12	C0010346; Crohn Disease; Disease or Syndrome
T13	PROC 1252 1263	Diagnóstico
#11	AnnotatorNotes T13	C0011900; Diagnosis; Diagnostic Procedure
T14	DISO 1278 1280	EC
#12	AnnotatorNotes T14	C0010346; Crohn Disease; Disease or Syndrome
T15	ANAT 1324 1329	heces
#13	AnnotatorNotes T15	C0015733; Feces; Body Substance
T16	DISO 1350 1365	dolor abdominal
#14	AnnotatorNotes T16	C0000737; Abdominal Pain; Sign or Symptom
T18	DISO 1411 1430	enfermedad de Crohn
#16	AnnotatorNotes T18	C0010346; Crohn Disease; Disease or Syndrome
T19	CHEM 1679 1691	Risankizumab
#17	AnnotatorNotes T19	C4505511; risankizumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T20	DISO 1650 1667	hipersensibilidad
#18	AnnotatorNotes T20	C0020517; Hypersensitivity; Pathologic Function | C0429891; Hypersensitivity finding; Finding
T21	CHEM 1700 1711	excipientes
#19	AnnotatorNotes T21	C0015237; Pharmaceutical Excipient; Biomedical or Dental Material
T22	CHEM 1733 1741	fármacos
#20	AnnotatorNotes T22	C0013227; Pharmaceutical Preparations; Pharmacologic Substance | C0456386; Medicament; Pharmacologic Substance
T23	CHEM 1762 1781	ingredientes de CHO
T24	DISO 1797 1819	acontecimiento adverso
#21	AnnotatorNotes T24	C0877248; Adverse event; Pathologic Function
T25	PROC 1992 2004	tratamientos
#22	AnnotatorNotes T25	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T26	CHEM 239 251	risankizumab
#23	AnnotatorNotes T26	C4505511; risankizumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T27	CHEM 578 590	risankizumab
#24	AnnotatorNotes T27	C4505511; risankizumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T28	ANAT 1356 1365	abdominal
#25	AnnotatorNotes T28	C0000726; Abdomen; Body Location or Region | C1281594; Entire abdomen; Body Part, Organ, or Organ Component
T29	ANAT 1778 1781	CHO
#26	AnnotatorNotes T29	C0085080; Chinese Hamster Ovary Cell; Cell
T30	Date 13 17	2016
T31	Duration 161 171	52 semanas
T32	LIVB 255 262	sujetos
#27	AnnotatorNotes T32	C0681850; Study Subject; Group
T33	Duration 500 510	52 semanas
T34	LIVB 594 601	sujetos
#28	AnnotatorNotes T34	C0681850; Study Subject; Group
T35	LIVB 856 863	Sujetos
#29	AnnotatorNotes T35	C0681850; Study Subject; Group
T36	LIVB 1062 1069	mujeres
#30	AnnotatorNotes T36	C0043210; Woman; Population Group
T37	Age 1070 1085	de 18 a 80 años
T38	Age 1097 1123	de 16 a menores de 18 años
T39	Duration 1448 1464	al menos 3 meses
T40	LIVB 1517 1524	Sujetos
#31	AnnotatorNotes T40	C0681850; Study Subject; Group
T41	LIVB 1544 1556	investigador
#32	AnnotatorNotes T41	C0035173; Research Personnel; Professional or Occupational Group
T42	LIVB 1638 1645	Sujetos
#33	AnnotatorNotes T42	C0681850; Study Subject; Group
T43	LIVB 1876 1888	Investigador
#34	AnnotatorNotes T43	C0035173; Research Personnel; Professional or Occupational Group
T44	LIVB 1901 1907	sujeto
#35	AnnotatorNotes T44	C0681850; Study Subject; Group
T46	LIVB 1943 1950	Sujetos
#36	AnnotatorNotes T46	C0681850; Study Subject; Group
T48	LIVB 1052 1059	Varones
#37	AnnotatorNotes T48	C0025266; Male population group; Population Group
T49	PROC 1201 1207	Tanner
#38	AnnotatorNotes T49	C0431029; Tanner bone age assessment; Diagnostic Procedure
A1	Status T20 History_of
A2	Status T24 History_of
A3	Status T25 History_of
#39	AnnotatorNotes T1	C1096776; Multicenter Study; Research Activity + C0034656; Randomization; Research Activity + C0013072; Double-Blind Method; Research Activity + C0599724; placebo controlled study; Research Activity · Intellectual Product 
#40	AnnotatorNotes T6	C1096776; Multicenter Study; Research Activity + C0034656; Randomization; Research Activity + C0013072; Double-Blind Method; Research Activity + C0599724; placebo controlled study; Research Activity · Intellectual Product
T45	Neg_cue 1908 1910	no
T47	Observation 1915 1941	adecuado para este estudio
A4	Assertion T47 Negated
#41	AnnotatorNotes T47	C1302261; Patient eligible for clinical trial; Finding (?)
T50	Neg_cue 1955 1957	no
T51	Observation 1958 2004	cumplan con los requerimientos de tratamientos
A5	Assertion T51 Negated
#42	AnnotatorNotes T51	C1532652; Drug therapy compliance finding; Finding (?)
R1	Negation Arg1:T45 Arg2:T47	
R2	Negation Arg1:T50 Arg2:T51	
R3	Has_Duration_or_Interval Arg1:T2 Arg2:T31	
T52	CONC 1477 1490	línea de base
#43	AnnotatorNotes T52	C1442488; Baseline; Quantitative Concept
T53	Quantifier_or_Qualifier 1284 1300	moderada a grave
#44	AnnotatorNotes T53	C1299393; Moderate to severe; Qualitative Concept
R4	Has_Quantifier_or_Qualifier Arg1:T14 Arg2:T53	
T54	Observation 1310 1329	frecuencia de heces
#45	AnnotatorNotes T54	C0426642; Frequency of bowel action; Finding
R5	Overlap Arg1:T14 Arg2:T54	
R6	Overlap Arg1:T14 Arg2:T16	
R7	Location_of Arg1:T28 Arg2:T16	
R9	Overlap Arg1:T16 Arg2:T18	
T55	PROC 1432 1438	SES-CD
#46	AnnotatorNotes T55	C5549856; Assessment using Simple Endoscopic Score for Crohn's Disease; Health Care Activity
T56	PROC 1373 1430	puntuación endoscópica simple para la enfermedad de Crohn
#47	AnnotatorNotes T56	C5549856; Assessment using Simple Endoscopic Score for Crohn's Disease; Health Care Activity
R10	Before Arg1:T13 Arg2:T52	
R11	Has_Duration_or_Interval Arg1:T14 Arg2:T39	
R12	Before Arg1:T14 Arg2:T52	
T57	Observation 1600 1620	candidato inadecuado
#48	AnnotatorNotes T57	C3242266; patient not eligible; Finding
R15	Has_Quantifier_or_Qualifier Arg1:T40 Arg2:T57	
T58	Observation 949 966	respuesta clínica
#49	AnnotatorNotes T58	C4055223; Clinical Response; Finding
R16	Experiences Arg1:T35 Arg2:T58	
T59	Observation 291 300	respondan
#50	AnnotatorNotes T59	C1319171; Medication response; Finding
R17	Overlap Arg1:T59 Arg2:T5	
T60	Observation 630 639	respondan
#51	AnnotatorNotes T60	C1319171; Medication response; Finding
R18	Overlap Arg1:T60 Arg2:T10	
R19	Experiences Arg1:T32 Arg2:T26	
R20	Experiences Arg1:T32 Arg2:T4	
R21	Experiences Arg1:T32 Arg2:T59	
R22	Has_Duration_or_Interval Arg1:T7 Arg2:T33	
R23	Experiences Arg1:T34 Arg2:T27	
R24	Experiences Arg1:T34 Arg2:T9	
R25	Experiences Arg1:T34 Arg2:T60	
R26	Experiences Arg1:T32 Arg2:T5	
R27	Experiences Arg1:T34 Arg2:T10	
T61	Observation 874 895	completado el estudio
A6	Status T61 History_of
#52	AnnotatorNotes T61	C2732579; Completion of clinical trial; Finding
T62	Observation 995 1019	participar en el estudio
#53	AnnotatorNotes T62	C1278516; Patient participation status; Finding
R28	Has_Age Arg1:T48 Arg2:T37	
R29	Has_Age Arg1:T36 Arg2:T37	
R30	Has_Age Arg1:T48 Arg2:T38	
R31	Has_Age Arg1:T36 Arg2:T38	
R32	Experiences Arg1:T48 Arg2:T49	
R33	Experiences Arg1:T36 Arg2:T49	
T63	Result_or_Value 1208 1215	etapa 5
R34	Has_Quantifier_or_Qualifier Arg1:T44 Arg2:T47	
R35	Experiences Arg1:T42 Arg2:T20	
R36	Causes Arg1:T19 Arg2:T20	
R37	Causes Arg1:T21 Arg2:T20	
R38	Causes Arg1:T22 Arg2:T20	
R39	Causes Arg1:T23 Arg2:T20	
T64	PROC 1832 1840	Estudios
#54	AnnotatorNotes T64	C0008976; Clinical Trials; Research Activity
R40	Overlap Arg1:T24 Arg2:T64	
A7	Status T64 History_of
R41	Has_Quantifier_or_Qualifier Arg1:T24 Arg2:T47	
R46	Experiences Arg1:T42 Arg2:T24	
R47	Has_Quantifier_or_Qualifier Arg1:T42 Arg2:T47	
R49	Experiences Arg1:T44 Arg2:T20	
R53	Experiences Arg1:T44 Arg2:T24	
R54	Experiences Arg1:T46 Arg2:T25	
T65	PROC 2047 2055	Estudios
A8	Status T65 History_of
#55	AnnotatorNotes T65	C0008976; Clinical Trials; Research Activity
R55	Overlap Arg1:T25 Arg2:T65	
T66	Quantifier_or_Qualifier 2015 2028	concomitantes
#56	AnnotatorNotes T66	C0521115; Simultaneous; Temporal Concept
R56	Has_Quantifier_or_Qualifier Arg1:T25 Arg2:T66	
R57	Experiences Arg1:T32 Arg2:T2	
R58	Experiences Arg1:T34 Arg2:T7	
T67	PROC 675 683	estudios
#57	AnnotatorNotes T67	C0008976; Clinical Trials; Research Activity
A9	Status T67 History_of
T68	PROC 336 344	estudios
A10	Status T68 History_of
#58	AnnotatorNotes T68	C0008976; Clinical Trials; Research Activity
R59	Overlap Arg1:T5 Arg2:T68	
R60	Overlap Arg1:T59 Arg2:T68	
R61	Overlap Arg1:T60 Arg2:T67	
R62	Overlap Arg1:T10 Arg2:T67	
T69	Observation 713 734	completado el estudio
A11	Status T69 History_of
#59	AnnotatorNotes T69	C2732579; Completion of clinical trial; Finding
T70	PROC 727 734	estudio
#60	AnnotatorNotes T70	C0008976; Clinical Trials; Research Activity
A12	Status T70 History_of
R63	Before Arg1:T67 Arg2:T27	
R64	Before Arg1:T69 Arg2:T27	
R65	Before Arg1:T70 Arg2:T27	
R66	Before Arg1:T68 Arg2:T26	
T71	Observation 874 884;906 916	completado el estudio
#61	AnnotatorNotes T71	C2732579; Completion of clinical trial; Finding
T72	PROC 888 895	estudio
A13	Status T72 History_of
#62	AnnotatorNotes T72	C0008976; Clinical Trials; Research Activity
T73	PROC 909 916	estudio
A14	Status T73 History_of
#63	AnnotatorNotes T73	C0008976; Clinical Trials; Research Activity
T74	PROC 1033 1040	estudio
A15	Status T74 History_of
#64	AnnotatorNotes T74	C0008976; Clinical Trials; Research Activity
T75	PROC 1012 1019	estudio
#65	AnnotatorNotes T75	C0008976; Clinical Trials; Research Activity
T76	Observation 1030 1040;995 1008	el estudio participar en
#66	AnnotatorNotes T76	C1278516; Patient participation status; Finding
A16	Status T75 History_of
R67	Overlap Arg1:T51 Arg2:T65	
R68	Has_Result_or_Value Arg1:T49 Arg2:T63	
A17	Experiencer T46 Patient
A18	Experiencer T43 Other
A19	Experiencer T44 Patient
A20	Experiencer T42 Patient
A21	Experiencer T41 Other
A22	Experiencer T40 Patient
A23	Experiencer T36 Patient
A24	Experiencer T48 Patient
A25	Experiencer T35 Patient
A26	Experiencer T34 Patient
A27	Experiencer T32 Patient
